| 摘要 |
The invention relates to type A crystal of 5-[{6-(2-fluorobenzyl)oxy-2- naphthyl}methyl]-2,4-thiazolidinedione characterized to have characteristic absorption peaks (2.theta.) at 11.5.degree.~0.3.degree., 14.5.degree.~0.2.degree., 16.2.degree.~0.3.degree., 17.0.degree.~0.3.degree., 17.7.degree.~0.2.degree., 18.6.degree.~0.3.degree., 19.1.degree.~0.2.degree., 21.3.degree.~0.4.degree., 22.4.degree.~0.5.degree., 25.7.degree.~0.5.degree. and 28.3.degree.~0.5.degree. in a powder X-ray diffraction pattern, and also to a method for preparation thereof, and a pharmaceutical composition comprising the same. The crystal is excellent in stability, and has advantages in handling, storage, and pharmaceutical preparation. The invention also relates to type B, C and D crystals of said compound.
|
